Evidence map›Paper›PMID 42866520›Full record

ArticleCureus2026

Granulomatous Interstitial Nephritis Associated With Adalimumab Therapy in a Patient With Rheumatoid Arthritis: A Case Report.

Naif Alghamdi

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Naif AlghamdiNephrology, Security Forces Hospital, Riyadh, SAU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a 67-year-old female who presented with a history of asymptomatic rising of serum creatinine after receiving adalimumab therapy for rheumatoid arthritis (RA). A renal biopsy revealed granulomatous interstitial nephritis (GIN). After other causes of acute kidney injury were excluded, adalimumab was held, and steroid therapy was initiated. His kidney function improved. Based on this case report, adalimumab could be a rare cause of impaired kidney function and should not be considered a completely safe treatment or disregarded as a potential cause of renal complications, such as GIN, as diagnosed in our case.

Indexed as

acute kidney injuryadalimumabgranulomatous interstitial nephritisinterstial fibrosis and tubular atrophyrheumatoid arthritis

Identifiers

PMID42866520
PMCPMC13656830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.